Last reviewed · How we verify
dexmedetomidine 80 µg
Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.
Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system. Used for Sedation of intubated and mechanically ventilated patients in intensive care settings, Sedation and analgesia during procedural sedation, Perioperative anxiolysis and sedation.
At a glance
| Generic name | dexmedetomidine 80 µg |
|---|---|
| Also known as | precedex 100 µg/ml |
| Sponsor | Fayoum University Hospital |
| Drug class | Alpha-2 adrenergic receptor agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia and Sedation |
| Phase | FDA-approved |
Mechanism of action
Dexmedetomidine binds with high selectivity to alpha-2 adrenergic receptors, particularly in the locus coeruleus and other brainstem regions, leading to decreased norepinephrine release and reduced neuronal firing. This results in a unique sedative state characterized by maintained airway reflexes and the ability to be aroused, along with analgesic and anxiolytic effects. The drug is the active d-enantiomer of medetomidine and is approximately 1600-fold more selective for alpha-2 versus alpha-1 receptors.
Approved indications
- Sedation of intubated and mechanically ventilated patients in intensive care settings
- Sedation and analgesia during procedural sedation
- Perioperative anxiolysis and sedation
Common side effects
- Hypotension
- Bradycardia
- Hypertension (transient, initial)
- Dry mouth
- Tachycardia (rebound)
- Nausea
Key clinical trials
- Efficacy of Intravenous Nefopam, Dexmedetomidine, and Meperidine in Preventing Post-Spinal Anesthesia Shivering in Adult Patients Undergoing Lower Abdominal and Lower Limb Surgeries. (NA)
- Neurochemical Mechanisms of the Awake vs. Anesthetized Brain (EARLY_PHASE1)
- Effects of Dexmedetomidine vs Propofol in Patients With Intra-abdominal Sepsis (PHASE4)
- Dexamethasone Versus Dexmedetomidine (PHASE4)
- Techniques for Perioperative Analgesia for Live Liver Donors; A Pilot Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dexmedetomidine 80 µg CI brief — competitive landscape report
- dexmedetomidine 80 µg updates RSS · CI watch RSS
- Fayoum University Hospital portfolio CI